VAG
AIM

VisionPoint Advisory Group’s AIM ImmunoTech AIM Stock Holding History

VisionPoint Advisory Group’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-31
Closed -$1.43K – 909
2023
Q3 		$1.43K Buy
+31
New +$1.91K ﹤0.01% 601

Other funds holding AIM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return

VisionPoint Advisory Group's AIM Position: Q4 2023 in Review

VisionPoint Advisory Group sold out of AIM ImmunoTech (AIM) in Q4 2023, closing a stake of 31 shares — an estimated $1.43K sold.

VisionPoint Advisory Group first reported a position in AIM in Q3 2023 and held it in 1 quarter. The position peaked at $1.43K in Q3 2023. 33 funds tracked by Wall St. Rank hold AIM as of Q4 2023.

  • VisionPoint Advisory Group reported no remaining AIM ImmunoTech position as of Q4 2023 after selling out during the quarter.
  • VisionPoint Advisory Group sold 31 AIM ImmunoTech shares in Q4 2023, an estimated $1.43K.
  • VisionPoint Advisory Group first reported a position in AIM ImmunoTech in Q3 2023 and held it in 1 quarter.
  • VisionPoint Advisory Group's AIM ImmunoTech position peaked at $1.43K in Q3 2023.
  • 33 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2023.

Based on VisionPoint Advisory Group's 13F filing for Q4 2023, filed 7 Feb 2024.